Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
about
Long-term efficacy and safety of raltegravir in the management of HIV infection.Clinical use of HIV integrase inhibitors: a systematic review and meta-analysisRaltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.Role of raltegravir in HIV-1 management.Next-generation integrase inhibitors : where to after raltegravir?Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Virologic and immunologic effectiveness at 48 weeks of darunavir-ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical practice: a multicenter Brazilian cohort.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain.Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse EventsThe treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD).
P2860
Q27686870-7E107F9E-F2D2-4C96-8EC0-84D5CD7BF70FQ28484930-54904114-B2D6-46B3-854F-F2987A0F7F0EQ35789343-9CBFFCB8-380B-4850-A356-86CA22A96D34Q36759898-500AC8E9-7005-4B60-9406-16FD163B761EQ37653463-A43CE744-D562-43E6-A7B4-30189D5B1E57Q38002011-36E8040A-23A4-4EB0-B3F1-A10B1CAADD88Q38081866-AEE97835-496E-4053-9807-CE00579C97FCQ38570500-9E69B1A2-74E6-42AA-9939-FCD717F3E81FQ38910036-607814CA-5E8A-49FE-A80C-A7FD7DEAD94FQ40100018-0BAC785F-52E6-4136-8EAD-7274910CAB99Q40674380-7D504D52-699F-486F-A2EF-2E627C9138BAQ41990454-67F3E94B-6B13-4E73-84DB-11112BC308E1Q42242935-1725AA26-D750-4302-A543-49B60243E0C8Q47305467-A434B531-90FE-4EDE-85CD-4CDF290F03F9
P2860
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy and safety of raltegr ...... domized EASIER ANRS 138 trial.
@ast
Efficacy and safety of raltegr ...... domized EASIER ANRS 138 trial.
@en
type
label
Efficacy and safety of raltegr ...... domized EASIER ANRS 138 trial.
@ast
Efficacy and safety of raltegr ...... domized EASIER ANRS 138 trial.
@en
prefLabel
Efficacy and safety of raltegr ...... domized EASIER ANRS 138 trial.
@ast
Efficacy and safety of raltegr ...... domized EASIER ANRS 138 trial.
@en
P2093
P2860
P356
P1476
Efficacy and safety of raltegr ...... domized EASIER ANRS 138 trial.
@en
P2093
Constance Delaugerre
EASIER ANRS 138 Study Group
François Jeanblanc
Isabelle Charreau
Isabelle Madelaine-Chambrin
Jacques Reynes
Jean-Michel Molina
Jean-Pierre Aboulker
Joséphine Braun
Pierre de Truchis
P2860
P304
P356
10.1093/JAC/DKR269
P407
P577
2011-06-28T00:00:00Z